LifeStance Health Group, Inc. (NASDAQ:LFST) Stock Has Average Price Target of $13.12

LifeStance Health Group, Inc. (NASDAQ:LFST) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $13.12.

Several research analysts recently issued reports on LFST shares. Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Barclays increased their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Wall Street Zen downgraded LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Canaccord Genuity Group boosted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. upped their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 14th.

LifeStance Health Group Price Performance

LifeStance Health Group stock opened at $13.40 on Friday. The company’s fifty day moving average price is $12.48 and its 200 day moving average price is $9.34. LifeStance Health Group has a 1 year low of $4.77 and a 1 year high of $13.76. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a market capitalization of $5.12 billion, a P/E ratio of 103.08 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million for the quarter, compared to analysts’ expectations of $414.58 million. During the same period in the prior year, the company posted ($0.01) EPS. The business’s revenue for the quarter was up 26.1% on a year-over-year basis. As a group, equities research analysts anticipate that LifeStance Health Group will post 0.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CTO Vukasin Paunovich sold 42,067 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the transaction, the chief technology officer directly owned 205,379 shares of the company’s stock, valued at $2,643,227.73. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Lisa Miller sold 47,912 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the transaction, the chief operating officer owned 281,289 shares in the company, valued at approximately $3,051,985.65. This represents a 14.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 13,777,580 shares of company stock valued at $146,433,781. 3.50% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

Several large investors have recently made changes to their positions in LFST. Oregon Public Employees Retirement Fund increased its stake in LifeStance Health Group by 16.6% in the third quarter. Oregon Public Employees Retirement Fund now owns 60,500 shares of the company’s stock valued at $728,000 after acquiring an additional 8,600 shares during the last quarter. Profund Advisors LLC increased its position in shares of LifeStance Health Group by 7.1% in the third quarter. Profund Advisors LLC now owns 11,944 shares of the company’s stock valued at $144,000 after buying an additional 788 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of LifeStance Health Group by 24.2% in the 3rd quarter. ProShare Advisors LLC now owns 34,469 shares of the company’s stock valued at $415,000 after purchasing an additional 6,727 shares during the last quarter. Vise Technologies Inc. raised its stake in LifeStance Health Group by 38.8% during the 3rd quarter. Vise Technologies Inc. now owns 22,511 shares of the company’s stock worth $271,000 after acquiring an additional 6,294 shares in the last quarter. Finally, State of Wyoming boosted its stake in shares of LifeStance Health Group by 10.4% during the 3rd quarter. State of Wyoming now owns 75,836 shares of the company’s stock worth $912,000 after acquiring an additional 7,158 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.